Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Citations

Citations to this article as recorded by  

• Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
  Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
  BMJ.2024; : e076388.     CrossRef
• Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
  强江 郭
  Advances in Clinical Medicine.2024; 14(03): 561.     CrossRef
• Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
  Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
  Diabetes Research and Clinical Practice.2024; 211: 111650.     CrossRef
• Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
  Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
  Archives of Physiology and Biochemistry.2023; 129(1): 76.     CrossRef
• Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
• Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
  I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov
  South Russian Journal of Therapeutic Practice.2023; 4(1): 68.     CrossRef
• An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
  Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco,
  Antioxidants.2023; 12(6): 1235.     CrossRef
• Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
  Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich
  Profilakticheskaya meditsina.2023; 26(12): 95.     CrossRef
• Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
  Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
• Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
  Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
  Obesity.2022; 30(6): 1279.     CrossRef
• Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
  Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
  Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
• Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
  Kyung-Soo Kim
  The Journal of Korean Diabetes.2022; 23(2): 83.     CrossRef
• Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
  Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Intestinal microbiota in the treatment of metabolically associated fatty liver disease
  Ji-Shuai Wang, Jin-Chun Liu
  World Journal of Clinical Cases.2022; 10(31): 11240.     CrossRef
• Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
  I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
  Systemic Hypertension.2022; 19(1): 31.     CrossRef
• Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
  Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
  Nutrients.2022; 14(23): 4994.     CrossRef
• Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
  Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
  Preventive Nutrition and Food Science.2022; 27(4): 384.     CrossRef
• NAFLDin type 2 diabetes mellitus: Still many challenging questions
  Simona Cernea, Itamar Raz
  Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
• Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
  Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
  Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
• Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes Therapy.2021; 12(1): 171.     CrossRef
• Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
  Sook Jung Lee, Byung-Wan Lee
  The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
• Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
  A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
  Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
• NAFLD and its link with diabetes: Why we should be worried
  Louise Cremonesini, Emma Harkin
  Independent Nurse.2021; 2021(8): 20.     CrossRef
• Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
  Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
• Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
  Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
  Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
  The Lancet Gastroenterology & Hepatology.2020; 5(9): 829.     CrossRef
• Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
  Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
  Medicine.2020; 99(33): e21038.     CrossRef
• Metabolic liver disease in diabetes – From mechanisms to clinical trials
  Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
  Metabolism.2020; 111: 154299.     CrossRef
• Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
  Siôn A. Parry, Leanne Hodson
  Advances in Therapy.2020; 37(4): 1381.     CrossRef
• Diabetes and Metabolism Journal in 2020: Good to Great
  In-Kyung Jeong
  Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
• Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
  Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
• Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
  Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
  Pharmacological Research.2020; 159: 104984.     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
• Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
  Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
  Journal of Diabetes Investigation.2020; 11(5): 1238.     CrossRef
• Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
  Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
  Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef